A controlled trial of BCG immunotherapy in bronchogenic carcinoma treated by surgical resection |
| |
| Authors: | P. Roscoe S. Pearce S. Ludgate N. W. Horne |
| |
| Affiliation: | (1) Chest Unit, City Hospital, Edinburgh;(2) Department of Respiratory Diseases, University of Edinburgh, UK;(3) Present address: Cheltenham General Hospital, Cheltenham;(4) Present address: Dryburn Hospital, Durham;(5) Present address: Department of Radiotherapy, Western General Hospital, Edinburgh;(6) Cheltenham General Hospital, Sandford Road, Cheltenham, Great Britain |
| |
| Abstract: | Summary Ninety-two patients with bronchogenic carcinoma who were treated by surgical resection of the tumour were subsequently given immunotherapy with BCG (Glaxo). The study was strictly randomised into three groups. Twenty-nine patients received multipuncture BCG (50–250×106 viable units) and 26 patients intradermal BCG (0.4–0.9×106 viable units) treatment being given at 1, 2, 5, 9, 13 and 26 weeks after operation and every 26 weeks thereafter. Thirty-seven control patients did not receive BCG. The patients have been observed for 15–33 months. There was no significant difference in survival between the control group and the two immunotherapy groups or between the two immunotherapy groups. The tumour cell type and presence of mediastinal nodes significantly influenced overall survival but not the response to BCG immunotherapy. The possible reasons for the failure of BCG to prolong survival in this study are discussed. |
| |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ |
|
